# K131605: Elecsys Precicontrol CMV Igg, Elecsys CMV Igg Immunoassay

- Pathway: 510(k) (Traditional)
- Applicant: Roche Diagnostics
- Decided: Feb 28, 2014 after 270 days
- Product code: LFZ (Enzyme Linked Immunoabsorbent Assay, Cytomegalovirus)
- Device class: 2
- Regulation: 21 CFR 866.3175
- Recalls of this device: none
- Data: FDA decisions to Oct 25, 2026; recalls to Oct 12, 2026

## Lineage
Longest line of descent: 2 generations back to K983805 (1999). 4 ancestors in all.
1 later device descends from it; 1 cites it directly.
0 of 6 devices in its family (counting itself) have a Class I recall.

## Predicates on the family tree (from the FDA summary)
- K981163: Diamedix IS-CMV Igg Test System, Diamedix Corp. (1998) Summary page 1.
- K072617: Elecsys Rubella Igg Immunoassay, Roche Diagnostics Corp. (2008) Summary page 1.

## Most influential descendants
- K220911: Elecsys CMV IgG (2022), 0 descendants of its own

## Indications for use
The Elecsys CMV IgG assay is an in vitro qualitative test for the detection of IgG antibodies to CMV in human serum, lithium-heparin plasma, K2-EDTA plasma, and K3-EDTA plasma. The test is intended as an aid in the determination of the serological status to CMV in individuals in which a CMV IgG test was ordered, including pregnant women. Performance characteristics have not been evaluated in immunocompromised or immunosuppressed individuals. This test is not intended for use in neonatal screening or for use at point of care facilities. This test is not intended for use in screening blood and plasma donors. The electrochemiluminescence immunoassay “ECLIA” is intended for use on Elecsys and cobas e immunoassay analyzers. Elecsys PreciControl CMV IgG is used for quality control of the Elecsys CMV IgG immunoassay on the Elecsys and cobas e immunoassay analyzers.

Source page: https://510kreport.com/device/K131605
Methodology: https://510kreport.com/methodology